

Topical Ketotifen 0.25% for Secondary Vestibulodynia

NCT07257029

Status	RECRUITING
Phase	Phase 2
Sponsor	Center for Vulvovaginal Disorders
Enrollment	54 participants

Key Eligibility Criteria

Inclusion (11)

- Female participants ≥18 years of age
- Able to provide signed and dated informed consent
- Able to read, write, understand, and complete English-language study-related forms and communicate in English
- Has a stable address and is available for the duration of the study
- In good general health based on medical history
- ... and 6 more (see full listing online)

Exclusion (15)

- Pregnancy or lactation
- Unable to tolerate the smallest dilator during baseline dilator assessment
- Active vaginal infection (Candida, BV, trichomonas, HSV)
- May re-screen after treatment and documented cure
- Active cutaneous disease of the vestibule
- ... and 10 more (see full listing online)

Locations (3 total)

The Center for Vulvovaginal Disorders - Washington, DC, Washington D.C., District of Columbia, United States
The Center for Vulvovaginal Disorders, Tampa, Florida, United States
The Center for Vulvovaginal Disorders - New York, New York, New York, United States